Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Isaly Samuel D
Relationship:   10% Owner
City:   New York
State:   NY
   
Insider Summary:
  
   
Companies Owned :   37    
Direct Shares   1,096,936    

Indirect Shares

   81,677,812      
Direct Value   $110    

Indirect Value

   $1,075,229,909      
Total Shares   82,774,748      
Total Value   $1,075,230,019      


American Cryostem Corporation $110 American Cryostem Corporation $110
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    4   
    0    

     Stock price went up :
    4   
    0    
     Stock price went down :
    0   
    0    
   
     Gain/Loss Ratio :
   4.0   
   0.0   
     Percentage Gain/Loss :
   54.4%
   0.0%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            American Cryostem Corporation CRYO Director, 10% Owner 2005-07-13 1,096,936 2005-07-13 1,231,936    Premium*  
            Volcano Corp VOLC Director 2006-06-20 0 2006-06-20 195,705    Premium*  
            Aryx Therapeutics Inc ARYX 10% Owner 2007-11-13 0 2009-05-22 1,340,139    Premium*  
            Albireo Pharma Inc ALBO Director 2008-02-12 0 2009-06-10 1,485,904    Premium*  
            Athersys Inc (New) ATHX 10% Owner 2008-05-21 0 2011-04-26 15,250    Premium*  
            Nxstage Medical, Inc. NXTM Director 2010-12-09 0 2010-12-09 2,690,476    Premium*  
            Kun Run Biotechnology Inc KURU 10% Owner 0 2010-04-30 5,228,758    Premium*  
            Anthera Pharmaceuticals Inc ANTH Director 2010-09-30 0 2013-01-30 7,462,000    Premium*  
            Amarin Corp Plc AMRN Director 0 2012-09-04 5,700    Premium*  
            Pacira Pharmaceuticals, Inc. PCRX 10% Owner 0 2012-03-12 2,446,000    Premium*  
            Chemocentryx, Inc. CCXI 10% Owner 2012-02-13 0 2012-02-13 908,509    Premium*  
            Supernus Pharmaceuticals Inc SUPN Director, 10% Owner 2012-05-04 0 2012-05-04 297,815    Premium*  
            Mirati Therapeutics, Inc. MRTX 10% Owner 0 2015-02-03 1,267,000    Premium*  
            Acceleron Pharma Inc XLRN Former 10% Owner 2013-09-24 0 2013-09-24 576,889    Premium*  
            Relypsa Inc RLYP 10% Owner 2013-11-20 0 2016-07-25 3,356,400    Premium*  
            Roka Bioscience, Inc. ROKA 10% Owner 0 2017-10-03 0    Premium*  
            Loxo Oncology, Inc. LOXO Director 2014-08-06 0 2017-12-08 941,000    Premium*  
            Otonomy, Inc. OTIC Director 2014-08-18 0 2015-11-30 1,850,094    Premium*  
            Sientra, Inc. SIEN 10% Owner 0 2015-10-12 17,100    Premium*  
            Pieris Pharmaceuticals, Inc. PIRS 10% Owner 0 2018-01-03 49,270    Premium*  
            Glaukos Corp GKOS Director 2015-06-30 0 2017-09-05 7,895    Premium*  
            Dimension Therapeutics, Inc. DMTX Director, 10% Owner 2015-10-27 0 2015-10-27 5,397,698    Premium*  
            Adaptimmune Therapeutics PLC ADAP Director 0 2017-03-27 6,149,377    Premium*  
            Viewray, Inc. VRAY Director, 10% Owner 0 2017-01-18 89,225    Premium*  
            Aeglea Biotherapeutics, Inc. AGLE 10% Owner 0 2017-02-21 1,469,524    Premium*  
            Intellia Therapeutics, Inc. NTLA Director 2016-05-11 0 2016-05-11 2,662,180    Premium*  
            Corvus Pharmaceuticals, Inc. CRVS Director, 10% Owner 2016-05-18 0 2016-06-24 5,379,349    Premium*  
            Selecta Biosciences Inc SELB Director, 10% Owner 0 2016-06-27 1,825,415    Premium*  
            Steadymed Ltd. STDY 10% Owner 0 2017-04-25 2,123,098    Premium*  
            Nabriva Therapeutics AG NBRV Director, 10% Owner 0 2016-12-30 391,960    Premium*  
            Aadi Bioscience, Inc AADI Director, 10% Owner 2017-03-15 0 2017-03-15 4,416,446    Premium*  
            Cti Biopharma Corporation CTIC 10% Owner 2017-06-13 0 2017-06-13 5,000,000    Premium*  
            Alpine Immune Sciences Inc ALPN Director, 10% Owner 2017-07-24 0 2017-07-24 3,298,516    Premium*  
            Kala Pharmaceuticals, Inc. KALA 10% Owner 2017-07-25 0 2018-01-12 2,692,715    Premium*  
            Audentes Therapeutics, Inc. BOLD 10% Owner 2017-09-07 0 2017-09-29 4,129,638    Premium*  
            Scpharmaceuticals Inc. SCPH 10% Owner 2017-11-21 0 2017-11-21 3,409,865    Premium*  
            X4 Pharmaceuticals Inc XFOR 10% Owner 2017-11-20 0 2017-11-20 1,868,966    Premium*  
* Premium Members only  

Records found :    251         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 7 of 11
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
OTIC Otonomy, Inc. Director   –       •      –    2015-11-17 4 S $28.80 $319,680 I/I (11,098) 2,245,300 0 -
OTIC Otonomy, Inc. Director   –       •      –    2015-11-19 4 S $28.60 $3,640,780 I/I (127,300) 2,118,000 0 -
OTIC Otonomy, Inc. Director   –       •      –    2015-11-20 4 S $28.59 $2,398,701 I/I (83,900) 2,034,100 0 -
OTIC Otonomy, Inc. Director   –       •      –    2015-11-23 4 S $28.45 $2,298,760 I/I (80,800) 1,953,300 0 -
OTIC Otonomy, Inc. Director   –       •      –    2015-11-24 4 S $28.75 $1,037,875 I/I (36,100) 1,917,200 0 -
OTIC Otonomy, Inc. Director   –       •      –    2015-11-25 4 S $28.91 $1,006,068 I/I (34,800) 1,882,400 0 -
OTIC Otonomy, Inc. Director   –       •      –    2015-11-27 4 S $28.97 $840,130 I/I (29,000) 1,853,400 0 -
OTIC Otonomy, Inc. Director   –       •      –    2015-11-30 4 S $28.64 $95,026 I/I (3,306) 1,850,094 0 -
RLYP Relypsa Inc 10% Owner   –       –       •   2015-12-21 4 S $27.50 $6,887,612 I/I (250,000) 7,650,000 0 -
RLYP Relypsa Inc 10% Owner   –       –       •   2015-12-22 4 S $26.39 $3,982,837 I/I (150,000) 7,500,000 0 -
RLYP Relypsa Inc 10% Owner   –       –       •   2015-12-23 4 S $26.78 $2,717,564 I/I (100,000) 7,400,000 0 -
NTLA Intellia Therapeutics, In... Director   –       •      –    2016-05-11 4 A $0.00 $0 I/I 2,412,180 2,412,180 0 -
NTLA Intellia Therapeutics, In... Director   –       •      –    2016-05-11 4 B $18.00 $4,500,000 I/I 250,000 2,662,180 2.1 -
CRVS Corvus Pharmaceuticals, I... Director   –       •      –    2016-05-18 4 B $11.55 $48,510 I/I 4,200 5,262,650 2.1 -
CRVS Corvus Pharmaceuticals, I... Director   –       •      –    2016-05-19 4 B $12.11 $31,525 I/I 2,600 5,265,250 2.1 -
ADAP Adaptimmune Therapeutics ... Director   –       •      –    2016-05-20 4 B $10.04 $24,096 I/I 2,400 28,043,404 2.1 -
CRVS Corvus Pharmaceuticals, I... Director   –       •       •   2016-05-20 4 B $13.09 $61,732 I/I 4,716 5,269,966 2.25 -
ADAP Adaptimmune Therapeutics ... Director   –       •      –    2016-05-23 4 B $10.40 $12,392,640 I/I 1,191,600 29,235,004 2.1 -
ADAP Adaptimmune Therapeutics ... Director   –       •      –    2016-05-24 4 B $10.48 $5,432,832 I/I 518,400 29,753,404 2.1 -
CRVS Corvus Pharmaceuticals, I... Director   –       •       •   2016-06-09 4 B $12.95 $388,500 I/I 30,000 5,299,966 2.25 -
CRVS Corvus Pharmaceuticals, I... Director   –       •       •   2016-06-10 4 B $12.98 $259,600 I/I 20,000 5,319,966 2.25 -
CRVS Corvus Pharmaceuticals, I... Director   –       •       •   2016-06-14 4 B $12.71 $127,100 I/I 10,000 5,329,966 2.25 -
CRVS Corvus Pharmaceuticals, I... Director   –       •       •   2016-06-15 4 B $11.94 $59,700 I/I 5,000 5,334,966 2.25 -
CRVS Corvus Pharmaceuticals, I... Director   –       •       •   2016-06-16 4 B $12.04 $60,200 I/I 5,000 5,339,966 2.25 -
CRVS Corvus Pharmaceuticals, I... Director   –       •       •   2016-06-17 4 B $12.48 $153,504 I/I 12,300 5,352,266 2.25 -
  251  Records found
  1   2   3   4   5   6   7  8   9   10   11      
  Page 7 of 11  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us